ROCHE HOLDING LTD S/ADR - RHHBY STOCK NEWS

Welcome to our dedicated page for ROCHE HOLDING S/ADR news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on ROCHE HOLDING S/ADR stock.

Roche Holdings Ltd. S/ADR (RHHBY) is a leading biotechnology company with a global presence in the field of in-vitro diagnostics. Roche focuses on scientific excellence to develop medicines and diagnostics for improving and saving lives. The company's pivotal role in personalized healthcare is reflected in its commitment to transforming healthcare delivery. Roche's innovative approach encompasses the discovery and development of cutting-edge treatments, including the first CD20xCD3 bispecific antibody, Columvi® (glofitamab), for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company's recently FDA-cleared whole-slide imaging system, VENTANA DP 200, signifies Roche's dedication to revolutionizing pathology workflows through digitalization and artificial intelligence-based tools, ensuring pathologists can provide accurate and timely diagnoses. Roche's extensive portfolio and pipeline of haematology medicines demonstrate its unwavering commitment to advancing treatment options for patients worldwide.

07/20/2023 01:00 AM

News

New Clinical and Real-World Data for Genentech’s Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss

Rhea-AI Summary

Genentech, a member of the Roche Group, will present data on its ophthalmology portfolio, including Vabysmo, at the 2023 ASRS Annual Meeting. The data highlight the efficacy of Vabysmo in treating wet AMD and DME, with positive anatomical outcomes and real-world evidence supporting its use. Vabysmo is currently approved in over 70 countries and has distributed over one million doses globally.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.23%

Tags

07/19/2023 09:39 AM

News

Roche to showcase next-generation diagnostic solutions at the American Association of Clinical Chemistry 2023 Clinical Lab Expo

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.48%

Tags

07/13/2023 01:00 AM

News

Positive Phase III results for Roche’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.49%

Tags

07/13/2023 01:00 AM

News

Positive Phase III Results for Genentech’s Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis

Rhea-AI Summary

Genentech, a member of the Roche Group, announced that the Phase III OCARINA II trial evaluating Ocrevus as a subcutaneous injection met its primary and secondary endpoints. The injection was shown to be non-inferior to Ocrevus given by intravenous infusion and was comparable in controlling MRI lesion activity. The safety profile of the injection was consistent with that of the IV infusion. The 10-minute injection has the potential to expand the usage of Ocrevus in MS centers without IV infrastructure or with IV capacity limitations.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.49%

Tags

07/11/2023 01:00 AM

News

European Commission approves Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma

Rhea-AI Summary

Roche's Columvi receives conditional marketing authorization in Europe for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Columvi is the first CD20xCD3 T-cell-engaging bispecific antibody available in Europe for this indication. It has the potential to change the current standard of care in DLBCL by inducing early and long-lasting responses and providing a treatment-free period. The approval is based on positive results from a pivotal study.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.51%

Tags

06/30/2023 11:50 AM

News

Four-year follow up data for Roche’s Evrysdi show continued increase in number of children with a severe form of spinal muscular atrophy (SMA) able to sit, stand and walk

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.24%

Tags

06/30/2023 11:50 AM

News

Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal Muscular Atrophy (SMA) Able to Sit, Stand and Walk

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.24%

Tags

06/27/2023 09:03 AM

News

Roche receives FDA clearance for additional Alzheimer's disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment decision-making

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.61%

Tags

06/15/2023 07:59 PM

News

FDA Approves Genentech’s Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.96%

Tags

06/13/2023 01:00 AM

News

Roche awarded WHO prequalification for the cobas® HPV test, increasing access to cervical cancer screening tools in low and lower-middle income countries

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.13%

Tags

FAQ

What is the current stock price of ROCHE HOLDING S/ADR (RHHBY)?

The current stock price of ROCHE HOLDING S/ADR (RHHBY) is $35.44 as of November 22, 2024.

What is the market cap of ROCHE HOLDING S/ADR (RHHBY)?

The market cap of ROCHE HOLDING S/ADR (RHHBY) is approximately 230.4B.

What is Roche Holdings Ltd. S/ADR (RHHBY) known for?

Roche is a global leader in biotechnology, specializing in in-vitro diagnostics and the development of cutting-edge medicines.

What is the significance of Columvi® (glofitamab) in Roche's portfolio?

Columvi® (glofitamab) is the first CD20xCD3 bispecific antibody that has shown promising results in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

How does Roche contribute to personalized healthcare?

Roche aims to transform healthcare delivery by focusing on scientific excellence, data insights, and partnerships with stakeholders to provide tailored treatment options for patients.

What recent innovation has Roche introduced in digital pathology?

Roche's VENTANA DP 200 whole-slide imaging system, with FDA clearance, allows pathologists to review and interpret digital pathology images efficiently, facilitating remote diagnosis and collaboration.

What is Roche's approach to advancing haematology treatments?

Roche has a robust portfolio and pipeline of haematology medicines, including T-cell engaging bispecific antibodies like Columvi®, to address the diverse needs of patients with blood cancers.